Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation

NCT05149365 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

190

Enrollment

OTHER

Sponsor class

Conditions

Acute-graft-versus-host Disease
Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Sitagliptin + Standard Prophylaxis
DRUG: Standard Prophylaxis

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]